Clinical DataPositive data from the IGNYTE registrational cohort of RP1 in combination with nivolumab in anti-PD-1-failed melanoma supports the potential approval of RP1.
Commercial StrategyThe Investor Day showcased the RP1 commercial strategy in melanoma and the broader RPx platform efforts, reinforcing a supportive view of the stock.
Regulatory ApprovalThe FDA has accepted Replimune Group's BLA for RP1 and granted priority review, with no advisory committee planned, indicating confidence in the drug's potential approval.